Institute for Clinical and Economic Review to Assess Treatments for Bladder Cancer
February 21, 2020
February 21, 2020
BOSTON, Massachusetts, Feb. 21 -- The Institute for Clinical and Economic Review issued the following announcement on Feb. 20:
The Institute for Clinical and Economic Review (ICER) announced that it plans to assess the comparative clinical effectiveness and value of nadofaragene firadenovec (Instiladrin(R), FKD Therapies Oy and Ferring Pharmaceuticals) for the treatment of bladder cancer. Nadofaragene firadenovec has received a fast track and breakthrough therapy designation from t . . .
The Institute for Clinical and Economic Review (ICER) announced that it plans to assess the comparative clinical effectiveness and value of nadofaragene firadenovec (Instiladrin(R), FKD Therapies Oy and Ferring Pharmaceuticals) for the treatment of bladder cancer. Nadofaragene firadenovec has received a fast track and breakthrough therapy designation from t . . .